Becton, Dickinson and Company $BDX Shares Purchased by Cinctive Capital Management LP

Cinctive Capital Management LP lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 71.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,847 shares of the medical instruments supplier’s stock after purchasing an additional 7,028 shares during the quarter. Cinctive Capital Management LP’s holdings in Becton, Dickinson and Company were worth $3,153,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. Empowered Funds LLC increased its holdings in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares during the period. United Bank lifted its position in Becton, Dickinson and Company by 23.9% in the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after purchasing an additional 993 shares during the last quarter. Vise Technologies Inc. acquired a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $481,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Becton, Dickinson and Company by 7.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 70,292 shares of the medical instruments supplier’s stock valued at $12,108,000 after purchasing an additional 4,628 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BDX. Zacks Research lowered shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Citigroup decreased their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. TD Cowen raised their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Jefferies Financial Group cut their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Finally, Piper Sandler reiterated a “neutral” rating and set a $170.00 price target (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $195.46.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,416 shares of company stock valued at $674,693. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $159.32 on Monday. The company has a market capitalization of $45.36 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 11.55 and a beta of 0.24. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The stock has a fifty day moving average of $190.01 and a 200-day moving average of $189.97. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the previous year, the company earned $3.43 EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.